A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer Institute

项目摘要 该项目由临床科学家Stephen Chun提出，他是德克萨斯大学M.D.安德森医学博士 癌症中心(MDACC)旨在扩大由国家癌症研究所(NCI)赞助的放射肿瘤学试验 休斯顿地区定位(HAL)综合学术卫星计划，并支持他的国家领导地位 与NCI赞助的合作团体的努力。自从加入MDACC教职员工以来，Chun博士领导了 建立HAL放射临床试验计划，并担任放射肿瘤科临床主任 MDACHALS的研究。在他的领导下，出现了前所未有的增长(2016年为1% 到2021年，参加放射临床试验的HAL患者的比例将增加到14%。与NCI赞助的 合作团体，Chun博士目前担任备受瞩目的NRG的国家首席研究员(PI) 肿瘤学分析，NRG/Alliance A082002研究冠军，NRG-LU005 MDACC机构PI，并拥有 我是NRG肿瘤学-RTOG 1308的顶级参与者，该课程之前因糟糕而面临关闭的危险 应计费用。为了实现NCI资助的MDACC HALS试验目标，Chun博士将带头实施 和扩展翻译生物标记物计划，为NCI赞助的神经认知测试能力 中枢神经系统(CNS)癌症试验，以及临床研究的继续医学教育计划。 Chun博士热衷于解决医疗保健差距问题，并致力于建立一个跟踪工作流程 在HALS独立登记参加临床试验的妇女和代表性不足的少数族裔的人数 仔细审查患者的纳入和排除标准以及其中的因素，以减少人口统计差异。按顺序 为了开发新的研究能力，Chun博士将与议定书的领导一起参加一个日间研讨会，该研讨会 负责开发MDACC研究人员发起的放射试验，建立放射临床 新的和规划中的MDACC设施的研究计划，利用人工智能来捕获更多的患者 有资格参加试验，并继续与NCI赞助的合作团体开发概念。他会承诺 至少20%的精力(2.4个日历月)用于NCI赞助的临床研究，MDACC是 致力于支持Chun博士的努力和NCI支持的临床试验。HIS的主要目标是 职业生涯是在MDACC HALS中优先考虑和扩大机构和NCI赞助的试验，这与 这一R50筹资机制以及NCI更广泛的使命。

Project Summary This project, proposed by clinician scientist Stephen Chun, M.D. at the University of Texas, M.D. Anderson Cancer Center (MDACC) aims to expand the National Cancer Institute (NCI)-sponsored radiation oncology trial program in the Houston Area Location (HAL) integrated academic satellites and support his national leadership efforts with the NCI-sponsored cooperative groups. Since joining the MDACC faculty, Dr. Chun has led the establishment of the HAL radiation clinical trial program and is the Director of Radiation Oncology Clinical Research for the MDACC HALs. Under his leadership, there has been an unprecedented increase (1% in 2016 to 14% in 2021) in the proportion of HAL patients enrolled on radiation clinical trials. With the NCI-sponsored cooperative groups, Dr. Chun currently serves as national Principal Investigator (PI) of a high-profile NRG Oncology analysis, study champion of NRG/Alliance A082002, MDACC institutional PI of NRG-LU005, and has been a top enroller for NRG Oncology-RTOG 1308 that was previously in jeopardy for closure due to poor accrual. To achieve NCI-funded trial objectives in the MDACC HALs, Dr. Chun will spearhead the implementation and expansion of a translational biomarker program, neurocognitive testing capabilities for NCI-sponsored central nervous system (CNS) cancer trials, and the continuing medical education program on clinical research. Dr. Chun is passionate about addressing healthcare disparities and is committed to establish a workflow to track numbers of women and underrepresented minorities enrolled on clinical trials in the HALs, and independently scrutinize patient inclusion and exclusion criteria and factors among to reduce demographic disparities. In order to develop new research capabilities, Dr. Chun will join the leadership of the Protocol in a Day Workshop, which is responsible for developing MDACC investigator-initiated radiation trials, establish the radiation clinical research program at new and planned MDACC facilities, leverage artificial intelligence to capture more patients eligible for trials, and continue to develop concepts with the NCI-sponsored cooperative groups. He will commit a minimum of 20% of his effort (2.4 calendar months) to NCI-sponsored clinical research, and MDACC is committed to support Dr. Chun’s efforts and conduct of NCI-supported clinical trials. The primary objective of his career is to prioritize and expand institutional and NCI-sponsored trials in the MDACC HALs which aligns with this R50 funding mechanism as well as with the broader mission of NCI.